All In Biotech

Drug Trial Radar · NCT07281937

A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 206 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

206

Actual

Start

Nov 25, 2025

Primary completion

Jul 23, 2026

Study completion Jul 23, 2026

Sponsor

Lead sponsor
Verdiva Bio Dev LimitedIndustry
Sponsor type
Industry
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.

Conditions

  • Obesity
  • Overweight

Interventions

  • VRB-101Drug

    VRB-101 tablets will be administered orally.

  • PlaceboDrug

    Placebo tablets will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean percent change from baseline in body weightTime frame: From Baseline (Day 0) up to Week 21

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Study Site 103

    Anniston, Alabama

  • Clinical Study Site 109

    Cullman, Alabama

  • Clinical Study Site 110

    Phoenix, Arizona

  • Clinical Study Site 113

    Little Rock, Arkansas

  • Clinical Study Site 111

    Anaheim, California

  • Clinical Study Site 107

    Montclair, California

  • Clinical Study Site 118

    Tarzana, California

  • Clinical Study Site 119

    Decatur, Georgia

  • Clinical Study Site 116

    West Des Moines, Iowa

  • Clinical Study Site 106

    Wichita, Kansas

  • Clinical Study Site 122

    Southfield, Michigan

  • Clinical Study Site 121

    Omaha, Nebraska

  • Clinical Study Site 117

    Binghamton, New York

  • Clinical Study Site 101

    Rochester, New York

  • Clinical Study Site 120

    Charlotte, North Carolina

  • Clinical Study Site 108

    Monroe, North Carolina

  • Clinical Study Site 105

    Norman, Oklahoma

  • Clinical Study Site 114

    Duncansville, Pennsylvania

  • Clinical Study Site 115

    Knoxville, Tennessee

  • Clinical Study Site 112

    Dallas, Texas

  • Clinical Study Site 102

    San Antonio, Texas

  • Clinical Study Site 104

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.